June 18th, 2018

A full text version of this article is available.
To access article obtain online access here or login
Combination Therapy with Paclitaxel, Carboplatin and Megestrol Acetate for the Management of Advanced Stage or Recurrent Carcinoma of the Endometrium: A Phase II Study
Authors:  Kerri S. Bevis, M.D., Larry C. Kilgore, M.D., Ronald D. Alvarez, M.D., J. Michael Straughn, Jr., M.D., and Charles A. Leath, III, M.D.
  OBJECTIVE: To determine overall survival (OS), progression-free interval (PFI), and toxicity in patients with advanced stage or recurrent endometrial cancer (EMCA) treated with combination paclitaxel, carboplatin and megestrol acetate.

STUDY DESIGN: Patients with stage III/IV or recurrent EMCA were enrolled between October 2004 and April 2008 and received paclitaxel (175 mg/m2) and carboplatin (AUC 6) every 21 days for 6 cycles and megestrol acetate 40 mg orally 4 times daily for up to 5 years. Dose reductions were based on grade 3/4 hematologic toxicity. Survival was calculated from time of study enrollment.

RESULTS: A total of 28 patients were evaluable: 21 (75%) patients with stage III/IV disease and 7 (25%) with recurrent disease. Three patients with recurrence received prior radiation. Mean PFI was 40.2 months (29.750.6). Mean OS was 50.1 months (41.5 58.7). After a median 40.4 months (range, 5.668.4) of follow-up, 13 patients (46%) had no evidence of disease, 4 were alive with disease, and 10 were dead of disease. One patient died without evidence of disease. Twenty-three patients (82%) completed 6 cycles of chemotherapy. Ten patients experienced a dose reduction. Myelosuppression was common, with 22 patients (78%) experiencing grade 3/4 neutropenia and 6 patients (21%) experiencing grade 3/4 anemia. Three patients had a deep vein thrombosis. One patient experienced a pulmonary thromboembolus.

CONCLUSION: Combination therapy with paclitaxel, carboplatin and megestrol acetate demonstrates activity. Myelosuppression is common but can be managed with colony-stimulating factors. The addition of hormonal therapy to cytotoxic chemotherapy may improve survival.
Keywords:  carboplatin, chemotherapy, endometrial cancer, hormonal therapy, megestrol, paclitaxel, phase II trial
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from